GILEAD SCIENCES, INC. GILD Cash Flow

Gilead sciences, inc. (GILD)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
Operating Activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
1,538	2,689	-1,168	1,875	1,968	3	2,099	1,819	1,539	-3,836	2,712	3,069	2,699	3,099	3,325	3,497	3,567	4,685	4,592	4,497	4,332	3,462	2,724	3,650	2,223	786	785	767	717	759	671	706	437	661	737	742	647	626	702	709	852	799	670	569	586
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense
68	69	66	60	60	57	57	56	56	78	52	54	49	48	44	43	42	45	41	38	37	31	41	29	24	26	25	26	23	22	20	20	19	18	17	17	18	17	15	15	17	20	15	15	13
Amortization expense
281	281	281	288	299	301	301	300	301	319	245	244	245	244	255	241	241	233	237	235	232	244	227	237	217	101	43	47	50	50	50	47	46	54	55	57	62	59	53	42	42	43	41	37	25
Stock-based compensation expense
141	157	162	174	143	175	198	252	220	334	113	102	89	102	95	95	88	97	97	96	92	95	100	83	82	71	62	55	61	57	54	48	48	46	46	50	49	53	51	48	46	41	48	49	41
Excess tax benefits from stock-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	172	140	186	124	144	57	157	110	79	48	40	49	29	12	23	10	9	6	14	12	7	10	49	20	25	12	20
Tax benefits from exercise and vesting of stock-based awards
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	173	140	186	124	144	58	158	115	80	50	38	51	30	12	18	10	8	5	12	12	7	11	51	22	27	15	23
Deferred income taxes
56	2,894	-824	4	24	-299	12	-37	35	-45	-11	80	58	214	21	-131	15	-49	182	139	121	169	14	50	3	85	22	29	-39	60	0	29	-51	-20	-3	-19	-20	30	-72	-1	31	30	-9	9	11
Net unrealized loss (gain) from equity securities
-283	929	58	57	197	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Up-front and milestone expense related to collaborative and other arrangements
111	-	-	-	133	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development impairment
-	-	-	-	-	-	-	-	-	-	-	-	-	201	117	0	114	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	30	11	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-59	-25	-93	-26	-40	-8	-33	-81	-49	-77	-38	-150	-39	-20	-24	-50	-68	-528	-7	-30	3	152	-22	-26	-3	150	-18	-18	-8	-5	3	12	-13	95	-41	-13	7	9	-23	1	2	18	5	1	39
Changes in operating assets and liabilities:
Accounts receivable, net
376	251	-101	100	-32	-113	-90	-176	-101	-281	-355	419	-537	-422	-580	-381	191	-213	800	462	348	1,751	-505	214	1,118	88	45	-50	231	-37	19	-376	196	154	-0	114	107	-3	109	78	163	66	72	128	89
Inventories
-15	60	23	-3	15	119	157	20	14	174	65	9	5	214	177	83	14	196	25	264	370	-42	-122	-64	85	126	15	143	57	125	11	186	26	64	22	17	97	-67	-89	142	174	35	46	-18	11
Prepaid expenses and other
-46	82	191	-9	43	-154	-127	-93	-529	-47	-166	32	-177	-265	450	209	126	-77	40	179	-52	-58	-93	353	169	58	-42	-33	187	19	77	-42	75	27	-2	-34	23	64	6	6	-6	32	43	-10	0
Accounts payable
-109	81	24	35	-201	178	-24	-101	-92	85	-116	-137	-262	162	-48	172	-239	-62	-332	562	58	-214	15	-70	-20	-121	-41	34	30	-29	-84	122	107	171	-37	119	176	-146	-120	120	141	68	91	64	-20
Income taxes payable
-127	165	381	-25	-249	92	287	-1,220	-618	5,545	-120	96	-24	-19	384	440	205	-254	-51	425	149	397	-162	57	241	117	-129	30	12	7	26	-2	-99	25	33	20	31	-50	29	-15	-149	47	68	-0	50
Accrued liabilities and other
-550	335	-236	-71	-417	-190	-643	155	164	206	-675	328	-677	-767	223	489	360	725	572	515	1,530	757	379	711	166	93	-13	65	167	-80	120	166	110	185	7	37	61	22	66	12	18	29	95	-25	10
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21	304	61	19	-8	17	3	-7	11	-15	32	15	-3	-9	20	3	12	-36	-8	0	-20	-7	-2	71	-5	0	-17
Net cash provided by operating activities
1,436	2,580	2,899	2,088	1,577	2,345	2,212	1,573	2,270	2,753	2,694	3,526	2,925	3,539	4,393	4,985	4,130	5,795	4,096	5,658	5,701	3,021	4,044	4,185	1,568	726	753	953	672	706	745	1,290	452	978	897	943	820	724	739	699	670	955	860	622	641
Investing Activities:
Purchases of marketable debt securities
13,158	6,398	7,035	10,300	6,722	4,447	3,777	1,612	397	4,501	5,544	9,787	3,482	5,738	7,859	7,045	4,977	4,948	5,444	4,385	2,462	575	882	556	94	2	55	136	62	96	541	607	0	966	1,447	1,194	1,519	1,702	1,784	513	1,502	697	726	310	879
Proceeds from sales of marketable debt securities
9,656	3,001	2,958	989	575	321	525	455	221	1,474	1,337	4,456	3,173	2,663	3,793	3,624	2,959	2,328	1,321	894	249	330	238	156	83	267	66	93	65	397	67	6	56	5,151	1,273	939	1,285	1,225	206	1,327	273	254	194	404	587
Proceeds from maturities of marketable debt securities
3,449	4,759	7,610	3,518	6,511	7,315	5,482	6,777	4,762	3,657	2,222	1,208	734	569	347	341	443	348	223	110	38	25	9	4	14	20	17	32	6	19	23	2	0	281	157	179	169	92	285	134	171	72	123	111	127
Up-front and milestone payments related to collaborative and other arrangements
112	-	-	-	133	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of equity securities
8	-	-	-	56	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	25	-	-	-	-	-	-	-	-	-	-	-	-
Acquisitions, net of cash acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	378	0	0	0	10,751	0	0	367	221	-	-	-	-	-	-	-	-
Purchases of other investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Capital expenditures
171	203	200	185	237	248	167	297	212	220	129	123	118	169	198	204	177	166	286	171	124	167	135	91	164	68	37	45	38	269	66	37	23	26	64	26	14	23	10	16	11	26	18	20	164
Other
0	186	-104	120	182	182	-94	82	20	0	0	0	0	-	0	0	357	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-344	431	-2,095	-5,909	-244	2,735	2,025	5,241	4,354	-10,016	-2,114	-4,246	307	-2,675	-3,917	-3,284	-2,109	-2,438	-4,186	-3,552	-2,299	-405	-770	-487	-161	216	-8	-55	-407	50	-518	-634	-10,743	4,440	-80	-469	-300	-407	-1,394	932	-1,068	-397	-426	-1,063	-328
Financing Activities:
Proceeds from debt financing, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,967	-1	-2	3,968	0	0	0	0	-0	0	0	2,144	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from convertible note hedges
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	861	95	184	92	354	154	914	317	711	601	1,516	51	1,105	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of convertible note hedges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	26	0	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuances of senior notes, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	987	-	-	-	-	-	-	-	-
Proceeds from issuances of common stock
177	27	41	38	103	50	80	48	111	51	64	23	96	28	60	28	92	38	79	84	118	56	112	54	109	72	94	60	86	115	148	69	132	53	42	57	58	54	22	40	103	61	58	61	40
Proceeds from credit facilities, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Repayments of Credit Facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Repurchases of common stock
1,328	105	222	588	834	962	449	450	1,039	106	153	130	565	1,000	1,000	1,001	8,000	3,051	3,050	900	3,001	2,001	1,698	1,200	450	399	100	0	82	200	205	241	20	226	883	724	548	615	1,552	1,691	162	242	288	238	230
Repayments of debt and other obligations
500	0	1,500	500	750	0	1,750	0	4,500	1,721	30	30	30	730	5	1,120	126	234	113	451	199	1,919	421	1,020	1,419	2,215	89	1,787	347	789	350	350	350	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of other long-term obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1	0	-0	0	0	1	0	0	5	0	0	5	0	0
Excess tax benefits from stock-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	172	140	186	124	144	57	157	110	79	48	40	49	29	12	23	10	9	6	14	12	7	10	49	20	25	12	20
Payments of dividends
874	801	804	800	817	736	742	740	753	682	682	680	687	619	623	626	587	614	627	633	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-86	-17	-30	-7	-68	-22	-40	-10	-414	-189	-20	-63	-58	-27	-110	-52	-87	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Contributions from (distribution to) noncontrolling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	191	-70	20	96	-34	29	-56	71	60	16	3	98	69	36	-73	15	-44	-60	-25	88	37	-20	25	35	-15	-86	22
Net cash used in financing activities
-2,611	-896	-2,515	-1,857	-2,366	-1,670	-2,901	-1,152	-6,595	3,347	2,170	-880	-1,244	-2,348	2,797	-1,561	-8,613	-4,465	6,644	-5,341	-2,722	1,234	-5,772	-1,371	2,884	-845	-942	-557	-199	-510	-307	-474	1,855	3,526	-876	-1,371	485	-459	270	-1,165	16	-324	-425	-156	-145
Effect of exchange rate changes on cash and cash equivalents
-61	42	-55	-9	20	-39	-1	-71	26	-4	46	27	68	-96	51	30	56	-6	-6	17	-72	-32	-24	0	0	3	5	-1	-5	7	5	-7	2	29	62	-31	-77	27	-75	79	46	14	-24	-26	37
Net change in cash and cash equivalents
-1,580	2,157	-1,766	-5,687	-1,013	3,371	1,335	5,591	55	-3,920	2,796	-1,573	2,056	-1,580	3,324	170	-6,536	-1,114	6,548	-3,218	608	3,818	-2,522	2,327	4,291	101	-191	338	60	253	-74	173	-8,431	8,974	3	-930	928	-115	-459	545	-336	248	-16	-622	204